Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance.

ABSTRACT:

Background

Ticagrelor has many protective cardiovascular properties beyond potent antiplatelet action. This study aimed to compare the effects of ticagrelor versus clopidogrel on infarcted mass, quantified by cardiac magnetic resonance (CMR), in patients with ST-segment elevation acute myocardial infarction (STEMI).

Methods

Adult patients of both sexes with STEMI under a pharmaco-invasive strategy were included (n = 225). Patients were treated by thrombolysis within six hours of symptom onset and underwent angiography with percutaneous coronary interventions, when needed, within the first 24 hours. Prior to the invasive procedures, patients were randomly assigned to receive either ticagrelor or clopidogrel using a centralized computerized system. Patients were followed on a

SUBMITTER: Fonseca FA 

PROVIDER: S-EPMC12558520 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature